Ümit Yavuz MALKAN, Yahya BÜYÜKAŞIK, Hakan GÖKER, Haluk DEMİROĞLU, Elifcan ALADAĞ, Ümit AKMAN

Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Background/aim: Graft-versus-host disease (GVHD) is a crucial complication leading to significant morbidity and mortality allogeneic hematopoietic stem cell transplantation which occurs in approximately half of the transplant recipients. Suppression of tumorigenicity 2 (ST2) and regenerating islet-derived 3-alpha(Reg3a) might be important biomarkers to predict acute GVHD. Materials and methods: In the present study, blood samples were collected from 17 patients with acute GVHD and 12 control patients after allogeneic stem cell transplantation. ST2 and Reg3a were measured in plasma samples compared in patients with acute GVHD and the controls. Results: Median age of the study population was 42 years (range 19–49). When compared to controls, the mean ST2 levels was significant higher in acute GVHD (9794 ng/dL vs. 2646 ng/dL, P = 0.008). Mean Reg3a level did not show significant difference between control and acute GVHD group (8848 ng/dL vs. 5632 ng/dL, respectively, P = 0.190). Conclusion: The ST2 level might be used as a significant biomarker for predicting acute GVHD.Key words: Suppression of tumorigenicity 2, regenerating isletderived 3-alpha, graft-versus-host disease, allogeneic hematopoietic stem cell transplantation

PDF

___

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. New England Journal of Medicine 2010; 363 (22): 2091-2101. doi: 10.1056/NEJMoa1004383
2. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Experimental Hematology 2001; 29 (3): 259-277. doi: 10.1016/s0301- 472x(00)00677-9
3. Aladag E, Kelkitli E, Goker H. Acute graft-versus-host disease: a brief review. Turkish Journal of Hematology 2020; 37 (1): 1-4. doi: 10.4274/tjh.galenos.2019.2019.0157
4. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373 (9674): 1550-1561. doi: 10.1016/ S0140-6736(09)60237-3
5. Bacigalupo A. Management of acute graft-versus-host disease. British Journal of Haematology 2007; 137 (2): 87-98. doi: 10.1111/j.1365-2141.2007.06533.x
6. Levine JE, Logan B, Wu J, Alousi AM, Ho V et al. Blood, marrow transplant clinical trials n: graft-versus-host disease treatment: predictors of survival. Biology of Blood and Marrow Transplantation 2010; 16 (12): 1693-1699. doi: 10.1016/j. bbmt.2010.05.019
7. Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD. British Journal of Haematology 2013; 160 (3): 288-302. doi: 10.1111/bjh.12142
8. Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 2015; 125 (1): 199-205. doi: 10.1182/ blood-2014-06-584789
9. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011; 118 (25): 6702-6708. doi: 10.1182/blood-2011-08-375006
10. Hartwell MJ, Ozbek U, Holler E, Renteria AS, Major-Monfried H et al. An early-biomarker algorithm predicts lethal graftversus-host disease and survival. JCI Insight 2018; 3(16). doi: 10.1172/jci.insight.124015
11. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. The New England Journal of Medicine 2013; 369 (6): 529-539. doi: 10.1056/NEJMoa1213299